BioCryst Pharmaceuticals, Inc. $BCRX Shares Bought by Eversept Partners LP

Eversept Partners LP grew its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 117.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,992,895 shares of the biotechnology company’s stock after purchasing an additional 1,619,270 shares during the quarter. BioCryst Pharmaceuticals makes up about 1.2% of Eversept Partners LP’s portfolio, making the stock its 18th biggest holding. Eversept Partners LP owned approximately 1.42% of BioCryst Pharmaceuticals worth $23,345,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in BCRX. RA Capital Management L.P. acquired a new stake in BioCryst Pharmaceuticals during the 4th quarter worth $123,452,000. Deerfield Management Company L.P. boosted its stake in BioCryst Pharmaceuticals by 159.4% during the 3rd quarter. Deerfield Management Company L.P. now owns 12,169,000 shares of the biotechnology company’s stock worth $92,363,000 after purchasing an additional 7,477,000 shares during the last quarter. Baker BROS. Advisors LP acquired a new stake in BioCryst Pharmaceuticals during the 4th quarter worth $22,017,000. Qube Research & Technologies Ltd boosted its stake in BioCryst Pharmaceuticals by 152.3% during the 2nd quarter. Qube Research & Technologies Ltd now owns 2,373,489 shares of the biotechnology company’s stock worth $21,266,000 after purchasing an additional 1,432,824 shares during the last quarter. Finally, Bank of America Corp DE boosted its stake in BioCryst Pharmaceuticals by 97.9% during the 2nd quarter. Bank of America Corp DE now owns 2,841,155 shares of the biotechnology company’s stock worth $25,457,000 after purchasing an additional 1,405,498 shares during the last quarter. Institutional investors and hedge funds own 85.88% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently commented on BCRX shares. Weiss Ratings reiterated a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a report on Monday, June 1st. Wedbush reduced their price target on BioCryst Pharmaceuticals from $22.00 to $21.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Needham & Company LLC reduced their price target on BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating on the stock in a report on Wednesday, May 6th. Citizens Jmp lifted their price target on BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the stock a “market outperform” rating in a report on Thursday, May 7th. Finally, Wall Street Zen lowered BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 9th. Nine research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, BioCryst Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $20.70.

BioCryst Pharmaceuticals Stock Up 0.3%

NASDAQ BCRX opened at $8.95 on Thursday. BioCryst Pharmaceuticals, Inc. has a 52 week low of $6.00 and a 52 week high of $10.32. The business’s fifty day simple moving average is $8.92 and its 200-day simple moving average is $8.16. The firm has a market cap of $2.27 billion, a PE ratio of -5.03 and a beta of 0.57.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported ($2.98) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.06 by ($3.04). The company had revenue of $156.41 million during the quarter, compared to analysts’ expectations of $151.12 million. BioCryst Pharmaceuticals had a negative net margin of 51.71% and a negative return on equity of 76.36%. The firm’s quarterly revenue was up 7.5% on a year-over-year basis. During the same quarter last year, the firm posted $0.20 earnings per share. Research analysts expect that BioCryst Pharmaceuticals, Inc. will post -2.66 EPS for the current year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.